Pediatric methemoglobinemia in the emergency department: etiology, treatment patterns, and short-term outcomes

Purpose This study aimed to characterize the clinical and etiological features of pediatric methemoglobinemia presenting to a pediatric emergency department, with particular attention to procedure-related local anesthetic exposure, and to explore short-term treatment responses to methylene blue and intravenous ascorbic acid.Materials and methods This single-center retrospective study included patients presenting between November 1, 2022 1 November 2022 1 November 2022, and November 1, 2025 1 November 2025 1 November 2025, with methemoglobin levels ≥ 5% measured by co-oximetry. Demographic, clinical, laboratory, treatment, G6PD, genetic, and disposition data were collected. Baseline characteristics and early treatment responses were compared between patients receiving methylene blue and intravenous ascorbic acid.Results Twenty-four patients were included; the median age was 4 months (IQR, 2–5), and 21 (87.5%) were male. Median initial SpO2 was 88% (IQR, 85%–90%), initial methemoglobin was 25.5% (IQR, 21.4%–30.6%), and post-treatment methemoglobin was 5.8% (IQR, 2.6%–8.3%). Drug exposure accounted for 19 cases (79.2%), most commonly lidocaine (n = 10) and prilocaine (n = 7). Among the five patients without documented oxidant exposure, two had pathogenic CYB5R3 variants and two had likely pathogenic CYB5R3 variants. Eleven patients received methylene blue and 13 received intravenous ascorbic acid. Post-treatment methemoglobin was lower with methylene blue (2.6% vs. 7.8%; p = 0.024), whereas relative reduction did not differ significantly (88.8% vs. 72.8%; p = 0.118).Conclusion Methemoglobinemia predominantly affected young infants and was most often associated with procedure-related local anesthetic exposure, particularly in the context of circumcision. Topical oropharyngeal anesthetic exposure before intubation should also be recognized as a potential source of oxidant exposure. Treatment comparisons were exploratory, and underlying enzymatic or genetic susceptibility should be considered even when an acquired oxidant exposure is identified.

Authors

Institutions

Publication Details

Journal
Postgraduate Medicine
Published
2026-11-17
DOI
https://doi.org/10.1080/00325481.2026.2765028
Primary Topic
Methemoglobinemia and Tumor Lysis Syndrome
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pediatric methemoglobinemia in the emergency department: etiology, treatment patterns, and short-term outcomes

Ali Fettah, Asuman Begüm Taşbaşı, Betül Öztürk, Bilge Akkaya et al.
Postgraduate Medicine
Methemoglobinemia and Tumor Lysis Syndrome
article

Pediatric methemoglobinemia in the emergency department: etiology, treatment patterns, and short-term outcomes

Ali Fettah, Asuman Begüm Taşbaşı, Betül Öztürk, Bilge Akkaya, Ahmet Serkan Özcan, Ali Güngör, Nilden Tuygun, Orkun Aydın, Fatma Tuba YILDIRIM, Fatma Şule Erdem, Caner Cebeci
article en

Abstract

Purpose This study aimed to characterize the clinical and etiological features of pediatric methemoglobinemia presenting to a pediatric emergency department, with particular attention to procedure-related local anesthetic exposure, and to explore short-term treatment responses to methylene blue and intravenous ascorbic acid.Materials and methods This single-center retrospective study included patients presenting between November 1, 2022 1 November 2022 1 November 2022, and November 1, 2025 1 November 2025 1 November 2025, with methemoglobin levels ≥ 5% measured by co-oximetry. Demographic, clinical, laboratory, treatment, G6PD, genetic, and disposition data were collected. Baseline characteristics and early treatment responses were compared between patients receiving methylene blue and intravenous ascorbic acid.Results Twenty-four patients were included; the median age was 4 months (IQR, 2–5), and 21 (87.5%) were male. Median initial SpO2 was 88% (IQR, 85%–90%), initial methemoglobin was 25.5% (IQR, 21.4%–30.6%), and post-treatment methemoglobin was 5.8% (IQR, 2.6%–8.3%). Drug exposure accounted for 19 cases (79.2%), most commonly lidocaine (n = 10) and prilocaine (n = 7). Among the five patients without documented oxidant exposure, two had pathogenic CYB5R3 variants and two had likely pathogenic CYB5R3 variants. Eleven patients received methylene blue and 13 received intravenous ascorbic acid. Post-treatment methemoglobin was lower with methylene blue (2.6% vs. 7.8%; p = 0.024), whereas relative reduction did not differ significantly (88.8% vs. 72.8%; p = 0.118).Conclusion Methemoglobinemia predominantly affected young infants and was most often associated with procedure-related local anesthetic exposure, particularly in the context of circumcision. Topical oropharyngeal anesthetic exposure before intubation should also be recognized as a potential source of oxidant exposure. Treatment comparisons were exploratory, and underlying enzymatic or genetic susceptibility should be considered even when an acquired oxidant exposure is identified.

Postgraduate Medicine
Ankara Etlik City Hospital (TR)
Methemoglobinemia and Tumor Lysis Syndrome
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon